Drug Trial Radar · NCT06151210
Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis
Last checked: Nov 19, 2026Latest source record: Aug 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
467
Actual
Start
Jan 31, 2024
Primary completion
Jul 10, 2025
Study completion Jul 15, 2025
Sponsor
- Lead sponsor
- Dong-A ST Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the efficacy and safety of DA-5219 in patients with acute or chronic gastritis
Conditions
- Gastritis Acute
- Gastritis Chronic
Interventions
DA-5219Drug
1 tablet/day
Stillen® TabDrug
3 tablets/day
DA-5219 PlaceboDrug
1 tablet/day
Stillen® Tab PlaceboDrug
3 tablets/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement rate of gastric mucosal erosionTime frame: Change from baseline at 2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.